Erythrocytosis associated with cyclosporine inununosuppression therapy in kidney transplant patients can be safely treated with a low doses of an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker, according to a small study.
W. Morale and colleagues from the Centro Trapianti di Rene, I Clinica Chirurgica, Policlinico, Universita di Catania, in Catania, Italy, enrolled 20 men and two women with post-kidney transplantation erythrocytosis.
Patients were treated with the ACE inhibitor lisinopril 2.5 to 5 mg/day for a mean period of 15 months. During the treatment period, 27 percent of participants switched from lisinopril to an angiotensin II receptor antagonist because of side effects. The treatment with either the ACE inhibitor or the angiotensin II blocker resulted in a 15 percent reduction in patients’ haematocrit levels, and this reduction remained stable over time.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!